Effect of testosterone on inflammatory markers in the development of early atherogenesis in the testicular-feminized mouse model

Endocrine Research

Volumn 38, Issue 3, 2013, Pages 125-138

  Kelly, Daniel M ^a   Sellers, Donna J ^b   Woodroofe, M Nicola ^a   Jones, T Hugh ^b,c   Channer, Kevin S ^d  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b BARNSLEY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Androgen receptor; Chemokine; Cytokine; Fatty streak; Lipid

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; FRACTALKINE; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROGENESIS; ATHEROMA; BODY WEIGHT; CHOLESTEROL DIET; CONTROLLED STUDY; LIPID BLOOD LEVEL; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULITIS;

EID: 84878881479     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.3109/07435800.2012.735307     Document Type: Article

References (44)

1. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009;207:318-327
2. Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 2008;29:102-105
3. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828-837
4. Khaw KT, Barrett-Connor E. Blood pressure and endogenous testosterone in men: An inverse relationship. J Hypertens 1988;6:329-332
5. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebocontrolled study. Circulation 2000;102:1906-1911
6. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocr Metab 2004;89:3313-3318 (Pubitemid 38951897)
7. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004;90:871-876 (Pubitemid 39005930)
8. Bruck B, Brehme U, Gugel N, et al. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1997;17:2192-2199 (Pubitemid 28057121)
9. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis: A study in castrated, cholesterol-fed rabbits. Circulation Res 1999;84:813-819 (Pubitemid 29181488)
10. Nathan L, Shi W, Dinh H, et al. Testosterone inhibits early atherogenesis by conversion to estradiol: Critical role of aromatase. Proc Natl Acad Sci USA 2001;98:3589-3593 (Pubitemid 32220889)
11. Nettleship JE, Jones TH, Channer KS, Jones RD. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: An effect that is independent of the classic androgen receptor. Circulation 2007;116:2427-2434 (Pubitemid 350145077)
12. Bourghardt J, Wilhelmson ASK, Alexanderson C, et al. Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology 2010;151:5428-5437
13. Combadiere C, Potteaux S, Gao JL, et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003;107:1009-1016 (Pubitemid 36258725)
14. Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Investig 2003;111:333-340
15. Teupser D, Pavlides S, Tan M, Gutierrez-Ramos JC, Kolbeck R, Breslow JL. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci USA 2004;101:17795-17800 (Pubitemid 40051966)
16. Kimouli M, Miyakis S, Georgakopoulos P, Neofytou E, Achimastos AD, Spandidos DA. Polymorphisms of fractalkine receptor CX3CR1 gene in patients with symptomatic and asymptomatic carotid artery stenosis. J Atheroscler Thromb 2009;16:604-610
17. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997;385:640-644
18. Wong BW, Wong D, McManus BM. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 2002;11:332-338 (Pubitemid 35380022)
19. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM, Greaves DR. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 2003;108:2498-2504 (Pubitemid 37444412)
20. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Investig 2007;117:185-194 (Pubitemid 46048465)
21. Combadiere C, Potteaux S, Rodero M, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008;117:1649-1657 (Pubitemid 351482605)
22. Hatakeyama H, NishizawaM, Nakagawa A, Nakano S, Kigoshi T, Uchida K. Testosterone inhibits tumor necrosis factor-α-induced vascular cell adhesion molecule-1 expression in human aortic endothelial cells. FEBS Lett 2002;530:129-132 (Pubitemid 35248198)
23. Mukherjee TK, Dinh H, Chaudhuri G, Nathan L. Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: Implications in atherosclerosis. Proc Natl Acad Sci USA 2002;99:4055-4060 (Pubitemid 34252228)
24. Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL. Dihydrotestosterone decreases tumor necrosis factor-Alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocr Metab 2006;91:546-554 (Pubitemid 43236925)
25. Zhang X, Wang L, Jiang T, et al. Effects of testosterone and 17-β-estradiol on TNF-α-induced E-selectin and VCAM-1 expression in endothelial cells: Analysis of the underlying receptor pathways. Life Sci 2002;71:15-29 (Pubitemid 34518626)
26. Death AK, McGrath KC, Sader MA, et al. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-kappa B-dependent pathway. Endocrinology 2004;145:1889-1897 (Pubitemid 38402398)
27. Charest NJ, Zhou ZX, Lubahn DB, Olsen KL, Wilson EM, French FS. A frameshift mutation destabilizes androgen receptor messenger RNA in the Tfm mouse. Mol Endocrinol 1991;5:573-581
28. He WW, Kumar MV, Tindall DJ. A frame-shift mutation in the androgen receptor gene causes complete androgen insensitivity in the testicular-feminized mouse. Nucleic Acids Res 1991;19:2373-2378 (Pubitemid 21902973)
29. Murphy L, O'Shaughnessy PJ. Testicular steroidogenesis in the testicular feminized (Tfm) mouse: Loss of 17 alpha-hydroxylase activity. J Endocrinol 1991;131:443-449
30. Le Goascogne C, Sannanes N, Gouezou M, Baulieu EE, Robel P. Suppressed expression of the cytochrome P45017 alpha protein in the testicular feminized (Tfm) mouse testes. J Endocrinol 1993;139:127-130 (Pubitemid 23347865)
31. Jones RD, Pugh PJ, Hall J, Channer KS, Jones TH. Altered circulating hormone levels, endothelial function and vascular reactivity in the testicular feminised mouse. Eur J Endocrinol 2003;148:111-120 (Pubitemid 36176011)
32. Yesilova Z, Ozata M, Kocar IH, et al. The effects of gonadotropin treatment on the immunological features of male patients with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2000;85:66-70 (Pubitemid 32268791)
33. Ridker PM, Rifai PM, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-Alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-2153 (Pubitemid 30253042)
34. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 2000;148(2):209-214 (Pubitemid 30064452)
35. Luc G, Bard JM, Juhan-Vague I, et al.; PRIME Study Group. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: The PRIME Study. Arterioscler Thromb Vasc Biol 2003;23(7):1255-1261 (Pubitemid 36871282)
36. Esposito K, Giugliano D. Diet and inflammation: A link to metabolic and cardiovascular diseases. Eur Heart J 2006;27(1):15-20 (Pubitemid 41785926)
37. Tilg H, Moschen AR. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6(10):772-783 (Pubitemid 44453463)
38. Jones TH. Testosterone associations with erectile dysfunction, diabetes, and the metabolic syndrome. Eur Urol Suppl 2007;6:847-857 (Pubitemid 47285796)
39. Zitzmann M, Erren M, Kamischke A, Simoni M, Nieschlag E. Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men. J Clin Endocrinol Metab 2005;90:6603-6608 (Pubitemid 41759322)
40. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blinded placebo-controlled Moscow study. Clin Endocrinol 2010;73(5):602-612
41. Spinedi E, Suescun MO, Hadid R, Daneva T, Gaillard RC. Effects of gonadectomy and sex hormone therapy on the endotoxin-stimulated hypothalamo-pituitary-Adrenal axis: Evidence for a neuroendocrine-immunological sexual dimorphism. Endocrinology 1992;131:2430-2436
42. Dansky HM, Charlton SA, Harper MM, Smith JDT. B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1997;94:4642-4646 (Pubitemid 27194296)
43. Ni M, Wang Y, Zhang M, et al. Atherosclerotic plaque disruption induced by stress and lipopolysaccharide in apolipoprotein E knockout mice. Am J PhysiolHeart Circ Physiol 2009;296:H1598-606
44. Patel A, Jagadesham VP, Porter KE, Scott DJA, Carding SR. Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease. Eur J Vasc Endovasc Surg 2008;36:20-27 (Pubitemid 351877094)